David Elsley Purchases 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Director David Elsley bought 40,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was bought at an average cost of C$1.88 per share, with a total value of C$75,072.00.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock opened at C$1.96 on Thursday. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.39 and a quick ratio of 6.84. The firm has a 50 day simple moving average of C$2.40 and a 200 day simple moving average of C$2.71. Cardiol Therapeutics Inc. has a fifty-two week low of C$1.07 and a fifty-two week high of C$4.26. The firm has a market cap of C$136.96 million, a P/E ratio of -4.45 and a beta of 0.70.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.